About: Performance of six SARS-CoV-2 immunoassays in comparison with microneutralisation

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Performance of six SARS-CoV-2 immunoassays in comparison with microneutralisation Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Performance of six SARS-CoV-2 immunoassays in comparison with microneutralisation
Creator	Kuivanen, S Vapalahti, O Jääskeläinen, Anne Kallio-Kokko, Jarva, H Kallio-Kokko, H Kekäläinen, E Kurkela, S Lappalainen, M Loginov, R Aj, Jääskeläinen Lappalainen, Mj, Ahava Ahava, M Jääskeläinen, A
Source	Elsevier; Medline; PMC
abstract	There is an urgent need for reliable high-throughput serological assays for the management of the ongoing COVID-19 pandemic. Preferably, the performance of serological tests for a novel virus should be determined with clinical specimens against a gold standard, i.e. virus neutralisation. We compared the performance of six commercial immunoassays for the detection of SARS-CoV-2 IgG, IgA and IgM antibodies, including four automated assays [Abbott SARS-COV-2 IgG (CE marked), Diasorin Liaison® SARS-CoV-2 S1/S2 IgG (research use only, RUO), and Euroimmun SARS-CoV-2 IgG and IgA (CE marked)], and two rapid lateral flow (immunocromatographic) tests [Acro Biotech 2019-nCoV IgG/IgM (CE marked) and Xiamen Biotime Biotechnology SARS-CoV-2 IgG/IgM (CE marked)] with a microneutralisation test (MNT). Two specimen panels from serum samples sent to Helsinki University Hospital Laboratory (HUSLAB) were compiled: the patient panel (N=70) included sera from PCR confirmed COVID-19 patients, and the negative panel (N=81) included sera sent for screening of autoimmune diseases and respiratory virus antibodies in 2018 and 2019. The MNT was carried out for all COVID-19 samples (70 serum samples, 62 individuals) and for 53 samples from the negative panel. Forty-one out of 62 COVID-19 patients showed neutralising antibodies.The specificity and sensitivity values of the commercial tests against MNT, respectively, were as follows: 95.1%/80.5% (Abbott Architect SARS-CoV-2 IgG), 94.9%/43.8% (Diasorin Liaison SARS-CoV-2 IgG; RUO), 68.3%/87.8% (Euroimmun SARS-CoV-2 IgA), 86.6%/70.7% (Euroimmun SARS-CoV-2 IgG), 74.4%/56.1% (Acro 2019-nCoV IgG), 69.5%/46.3% (Acro 2019-nCoV IgM), 97.5%/71.9% (Xiamen Biotime SARS-CoV-2 IgG), and 88.8%/81.3% (Xiamen Biotime SARS-CoV-2 IgM). This study shows variable performance values. Laboratories should carefully consider their testing process, such as a two-tier approach, in order to optimize the overall performance of SARS- CoV-2 serodiagnostics.
has issue date	2020-06-15(xsd:dateTime)
bibo:doi	10.1016/j.jcv.2020.104512
bibo:pmid	32563180
has license	no-cc
sha1sum (hex)	6736a4254ea20359949e299b4cb0fa3b52c350ae
schema:url	https://doi.org/10.1016/j.jcv.2020.104512
resource representing a document's title	Performance of six SARS-CoV-2 immunoassays in comparison with microneutralisation
has PubMed Central identifier	PMC7295517
has PubMed identifier	32563180
schema:publication	J Clin Virol
resource representing a document's body	covid:6736a4254ea20359949e299b4cb0fa3b52c350ae#body_text
is schema:about of	named entity 'COVID-19' named entity '2019 in Finland' named entity 'IgG' named entity 'IgG' named entity 'SARS-CoV-2' named entity 'Rheumatoid factor' named entity 'lateral flow assays' named entity 'IgG/IgM' named entity 'immunoassays' named entity 'serum' named entity 'antigen' named entity 'Helsinki University Hospital' named entity 'SARS-CoV-2' named entity 'IgG' named entity 'IgA' named entity 'IgG' named entity 'lateral flow' named entity '99.9%' named entity '+358' named entity '+358' named entity 'Immunology' named entity 'IgG' named entity 'median age' named entity 'Finland' named entity 'seroconversion' named entity 'serum samples' named entity 'antigen' named entity 'antibodies' named entity 'IgG/IgM' named entity 'SARS-CoV-2' named entity 'immunoassays' named entity 'antigen' named entity 'IgG' named entity 'SARS-CoV-2' named entity 'IgG' named entity 'Xiamen' named entity 'autoantibody' named entity 'gold standard' named entity 'serum' named entity 'nucleoprotein' named entity 'antibodies' named entity 'positive reaction' named entity 'COVID-19' named entity 'prozone effect' named entity 'COVID' named entity 'autoantibodies' named entity 'IgG' named entity 'IgA' named entity 'immunoassays' named entity 'SARS-CoV-2' named entity 'CO2' named entity 'COVID-19 pandemic' named entity 'serological assay' named entity 'crystal violet' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'SARS-COV-2' named entity 'Department of Virology' named entity 'public health management' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'seroconversion' named entity 'DiaSorin' named entity 'IgG' named entity 'IgG' named entity '1:2' named entity 'growth medium'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software